These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34361048)

  • 21. [Chinese guideline for clinical diagnosis and treatment of malignant pleural mesothelioma (2021 Edition)].
    Multidisciplinary Committee of Oncology, Chinese Physicians Association
    Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):383-394. PubMed ID: 33902201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron signature in asbestos-induced malignant pleural mesothelioma: A population-based autopsy study.
    Crovella S; Bianco AM; Vuch J; Zupin L; Moura RR; Trevisan E; Schneider M; Brollo A; Nicastro EM; Cosenzi A; Zabucchi G; Borelli V
    J Toxicol Environ Health A; 2016; 79(3):129-41. PubMed ID: 26818092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
    Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
    Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
    Remon J; Nadal E; Dómine M; Ruffinelli J; García Y; Pardo JC; López R; Cilleruelo A; García-Campelo R; Martín P; Juan O; González-Larriba JL; Provencio M; Olmedo E; Ponce S; Cumplido D; Barenys C; Majem M; Massutti B; Rodriguez-Abreu D; Porta R; Sala MA; Martinez-Kareaga M; Lianes P; Reguart N
    Lung Cancer; 2020 Sep; 147():83-90. PubMed ID: 32682189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
    Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.
    Tsao A; Nakano T; Nowak AK; Popat S; Scagliotti GV; Heymach J
    Semin Oncol; 2019 Apr; 46(2):145-154. PubMed ID: 31280996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical feature of diagnostic challenging cases for pleural biopsy in patient with malignant pleural mesothelioma.
    Hashimoto M; Sato A; Kuroda A; Nakamura A; Nakamichi T; Kondo N; Yuki M; Nabeshima K; Tsujimura T; Hasegawa S
    Gen Thorac Cardiovasc Surg; 2020 Aug; 68(8):820-827. PubMed ID: 31981139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
    Facchetti G; Petrella F; Spaggiari L; Rimoldi I
    Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma.
    Villanova T; Gesmundo I; Audrito V; Vitale N; Silvagno F; Musuraca C; Righi L; Libener R; Riganti C; Bironzo P; Deaglio S; Papotti M; Cai R; Sha W; Ghigo E; Schally AV; Granata R
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2226-2231. PubMed ID: 30659154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review.
    Sheff KW; Hoda MA; Dome B; Hegedus B; Klepetko W; Weiss GJ
    Microrna; 2012; 1(1):40-8. PubMed ID: 25048089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.
    Tolani B; Acevedo LA; Hoang NT; He B
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-asbestos-related malignant pleural mesothelioma.
    Kanbay A; Ozer Simsek Z; Tutar N; Yılmaz I; Buyukoglan H; Canoz O; Demir R
    Intern Med; 2014; 53(17):1977-9. PubMed ID: 25175133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
    Bronte G; Incorvaia L; Rizzo S; Passiglia F; Galvano A; Rizzo F; Rolfo C; Fanale D; Listì A; Natoli C; Bazan V; Russo A
    Crit Rev Oncol Hematol; 2016 Nov; 107():20-32. PubMed ID: 27823648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
    Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
    Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapies currently in Phase II trials for malignant pleural mesothelioma.
    Pinton G; Manente AG; Tavian D; Moro L; Mutti L
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1255-63. PubMed ID: 23815672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural Polyphenols in Cancer Management: Promising Role, Mechanisms, and Chemistry.
    Upadhyay PK; Singh S; Vishwakarma VK
    Curr Pharm Biotechnol; 2024; 25(6):694-712. PubMed ID: 37608669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells.
    Bonelli M; Terenziani R; Zoppi S; Fumarola C; La Monica S; Cretella D; Alfieri R; Cavazzoni A; Digiacomo G; Galetti M; Petronini PG
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708306
    [No Abstract]   [Full Text] [Related]  

  • 40. Multiplex Soluble Biomarker Analysis from Pleural Effusion.
    Javadi J; Dobra K; Hjerpe A
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32731396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.